EGFR- and VEGF(R)-Targeted Small Molecules Show Synergistic Activity in Colorectal Cancer Models Refractory to Combinations of Monoclonal Antibodies-Reference-Cited by-同舟云学术

EGFR- and VEGF(R)-Targeted Small Molecules Show Synergistic Activity in Colorectal Cancer Models Refractory to Combinations of Monoclonal Antibodies

Published:2011-08-31 Issue:20 Volume:17 Page:6522-6530
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Poindessous Virginie,Ouaret Djamila,El Ouadrani Karima,Battistella Aude,Mégalophonos Virginie F.,Kamsu-Kom Nyam,Petitprez Amélie,Escargueil Alexandre E.,Boudou Pascaline,Dumont Sylvie,Cervera Pascale,Fléjou Jean-François,André Thierry,Tournigand Christophe,Chibaudel Benoist,de Gramont Aimery,Larsen Annette K.

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Signaling pathways in colorectal cancer: implications for the target therapies;Molecular Biomedicine;2024-06-07

2. Drug Resistance in Colorectal Cancer: From Mechanism to Clinic;Cancers;2022-06-14

3. Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies;Journal of Experimental & Clinical Cancer Research;2021-10-18

4. Recent insights in the PI3K/Akt pathway as a promising therapeutic target in combination with EGFR‐targeting agents to treat head and neck squamous cell carcinoma;Medicinal Research Reviews;2021-04-29

5. Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial;Experimental Hematology & Oncology;2020-04-20